M. Maurer

Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial

A. Luft, C. Nolte, S. Thilemann, 2021, The Lancet Neurology.

Pharmacokinetics And Pharmacogenetics Of Gemcitabine Combined With Epirubicin Or Cisplatin In Non-small Cell Lung Cancer Patients: 94

H. Groen, E. D. de Vries, J. Maring, 2005 .

Isotope-labelled urea to test colon drug delivery devices in vivo: principles, calculations and interpretations

K. Wutzke, R. Schellekens, F. Stellaard, 2013, Isotopes in environmental and health studies.

Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.

P. Toutain, J. N. King, M. Maurer, 2003, Journal of veterinary pharmacology and therapeutics.

Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs.

J. Steffan, G. Strehlau, M. Maurer, 2004, Journal of veterinary pharmacology and therapeutics.

Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model.

P. Schneider, O. Zak, W. Tosch, 1982, The Journal of antibiotics.

Gemcitabine and Epirubicin Plasma Concentration-Related Excretion in Saliva in Patients With Non–Small Cell Lung Cancer

H. Groen, E. D. de Vries, J. Maring, 2010, Therapeutic drug monitoring.

Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.

G. Kaiser, C. Mauron, J. N. King, 1997, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and pharmacogenetics of gemcitabine combined with epirubicin or cisplatin in non-small cell lung cancer patients

H. Groen, J. Maring, D. Uges, 2004 .